References
- Aisner J. Chemotherapy for small cell lung cancer. Lung Cancer. A Comprehensive Treatise., JD. Bitran, HM. Colomb, AG. Little, RR. Weichselbaum. Grune and Straton, Orlando 1988; 307–327
- Hoffman PC. The role of surgical resection in management of small cell carcinoma of the lung. Lung Cancer. A Comprehensive Treatise., JD. Bitran, HM. Colomb, AG. Little, RR. Weichselbaum. Grune and Stratton, Orlando 1988; 359–367
- Klastersky J. Therapy of small cell lung cancer: Anything new. Eur J Cancer Clin Oncol 1988; 24: 107–112
- Angeletti CA, Macchiarini P, Mussi A, et al. Influence of T and N stages on long-term survival in resectable small cell lung cancer. Eur J Surg Oncol 1989; 15: 337–340
- Baker RR, Ettinger DS, Ruckdeschel JD, et al. The role of surgery in the management of selected patients with small-cell carcinoma of the lung. J Clin Oncol 1987; 5: 697–702
- Mountain CF. Operation for small-cell carcinoma revised. J Clin Oncol 1987; 5: 687–688
- Friess GG, Mc Cracken JD, Troxell ML, et al. Effect of initial resection of small-cell carcinoma of the lung: a review of Southwest Oncology Group study 7628. J Clin Oncol 1985; 3: 964–968
- Graham BL, Balducci L, Khansur T, et al. Surgery in small cell lung cancer. Ann Thorac Surg 1988; 45: 687–692
- Mountain CF. A new international staging system for lung cancer. Chest 1986; 89: 225S–233S
- Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
- World Health Organization: The World Health Organization histological typing of lung tumors. Am J Clin Pathol 1982; 77: 123–136
- Matthews MJ, Gazdar AF. Pathology of small cell carcinoma of the lung and its subtypes. A clinico-pathologic correlation. Lung Cancer 1: Cancer Treatment and Research., RB. Livingston, Nijhoff Martinus, 1980; 283–306, The Hague
- Macchiarini P, Danesi R, Del Tacca M, et al. Effects of thymostimulin of chemotherapy-induced toxitity and long-term survival in small cell lung cancer patients. Anticancer Res 1989; 9: 193–196
- Richardson PJ. King's endomyocardial bioptome. Lancet 1972; 1: 660–661
- Billingham ME, Bristow MR. Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Symp 1984; 3: 71–76
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
- Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient. II. Analysis and Examples. Br J Cancer 1977; 35: 1–39
- Weiss RB, Sarosy G, Clagget-Carr K, et al. Anthracycline analogs: the past, present, and future. Cancer Chemother Pharmacol 1986; 18: 185–197
- Ganzina F. 4'-Epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rep 1983; 10: 1–22
- Cersosimo RJ, Hong WK. Epirubicin, a review of the pharmacology, clinical activity, and adverse effect of an adriamycin analogue. J Clin Oncol 1986; 4: 425–439
- Macchiarini P, Mussi A, Basolo F, et al. Optimal treatment of T1-3NOMO small cell lung cancer: surgery plus adjuvant chemotherarpy. Anticancer Res 1989; 9: 1623–1626
- Karrer K, Shields TW, Denck H, et al. The importance of surgical and multimodality treatment for small cell bronchial carcinoma. J Thorac Cardiovasc Surg 1989; 97: 168–176
- Frei E, III, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585–594
- Wittes RE. Adjuvant chemotherapy-clinical trials and laboratory models. Cancer Treat Rep 1986; 70: 87–103
- Macchiarini P, Hardin M, Chella A, et al. Surgery plus adjuvant chemotherapy for T1-3NOMO small cell lung cancer. Am J Clin Oncol, in press
- Macchiarini P, Danesi R, Mariotti R, et al. Phase II study of high-dose epirubicin in untreated small cell lung cancer. Am J Clin Oncol 1990; 13: 302–307
- Torti FM, Bristow MM, Lum BI. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 1986; 46: 3722–3727
- Einhorn LH, Crawford J, Birch R, et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol 1988; 6: 451–456